{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:41:37Z","timestamp":1791081697512,"version":"4.1.0"},"reference-count":172,"publisher":"European Respiratory Society (ERS)","issue":"177","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,5,14]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Connective tissue disease-associated interstitial lung disease is one of the most common subtypes of interstitial lung disease, which is a leading cause of morbidity and mortality in patients with these systemic autoimmune rheumatic diseases. A spectrum of disease trajectories exists within individual and across different connective tissue diseases. In individuals with connective tissue diseases who are at risk or at the early asymptomatic stage with interstitial lung changes, we have potential windows of opportunity for interventions to prevent the development of or progression to interstitial lung disease. In this perspective, we use systemic sclerosis and rheumatoid arthritis as sample cases to discuss emerging knowledge on disease pathogenesis, as well as to apply the preventative medicine concept for pharmacotherapeutic approaches at different disease stages of connective tissue disease-associated interstitial lung disease.<\/jats:p>","DOI":"10.1183\/16000617.0046-2025","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:30:19Z","timestamp":1753259419000},"page":"250046","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Treating connective tissue disease-associated interstitial lung disease \u2013 think outside the box: a perspective"],"prefix":"10.1183","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-9342","authenticated-orcid":false,"given":"Yet H.","family":"Khor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5295-2877","authenticated-orcid":false,"given":"Catharina C.","family":"Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Merkt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Buschulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"2025080602001242000_34.177.250046.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00457-9"},{"key":"2025080602001242000_34.177.250046.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27405"},{"key":"2025080602001242000_34.177.250046.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211448"},{"key":"2025080602001242000_34.177.250046.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.05.010"},{"key":"2025080602001242000_34.177.250046.5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00296-016-3638-5","article-title":"Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study","volume":"37","author":"van den Hoek","year":"2017","journal-title":"Rheumatol Int"},{"key":"2025080602001242000_34.177.250046.6","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.3390\/jcm10214830","article-title":"Interstitial lung disease in connective tissue diseases: survival patterns in a population-based cohort","volume":"10","author":"Hyldgaard","year":"2021","journal-title":"J Clin Med"},{"key":"2025080602001242000_34.177.250046.7","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0210-2022"},{"key":"2025080602001242000_34.177.250046.8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/art.42860","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025080602001242000_34.177.250046.9","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025080602001242000_34.177.250046.10","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1159\/000526575","article-title":"Costs of pharmacological and non-pharmacological interventions in interstitial lung disease management in Germany","volume":"101","author":"Maqhuzu","year":"2022","journal-title":"Respiration"},{"key":"2025080602001242000_34.177.250046.11","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1513\/AnnalsATS.201911-822OC","article-title":"Costs of workplace productivity loss in patients with connective tissue disease-associated interstitial lung disease","volume":"17","author":"Algamdi","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2025080602001242000_34.177.250046.12","unstructured":"Kisling LA , Das JM . Prevention strategies. In: StatPearls. Treasure Island, StatPearls Publishing, 2024."},{"key":"2025080602001242000_34.177.250046.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2025080602001242000_34.177.250046.14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/MCP.0000000000000908","article-title":"Epidemiology and real-life experience in progressive pulmonary fibrosis","volume":"28","author":"Valenzuela","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"2025080602001242000_34.177.250046.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00239-2023"},{"key":"2025080602001242000_34.177.250046.16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00404-2023"},{"key":"2025080602001242000_34.177.250046.17","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0053-2021"},{"key":"2025080602001242000_34.177.250046.18","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2572"},{"key":"2025080602001242000_34.177.250046.19","doi-asserted-by":"crossref","first-page":"e94775","DOI":"10.1371\/journal.pone.0094775","article-title":"Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis","volume":"9","author":"Kono","year":"2014","journal-title":"PLoS One"},{"key":"2025080602001242000_34.177.250046.20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00541"},{"key":"2025080602001242000_34.177.250046.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2010.02.001"},{"key":"2025080602001242000_34.177.250046.22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003148"},{"key":"2025080602001242000_34.177.250046.23","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-0980-7"},{"key":"2025080602001242000_34.177.250046.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.20515"},{"key":"2025080602001242000_34.177.250046.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104299"},{"key":"2025080602001242000_34.177.250046.26","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000325"},{"key":"2025080602001242000_34.177.250046.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.103013"},{"key":"2025080602001242000_34.177.250046.28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12016-021-08890-1","article-title":"Autoantibodies in rheumatoid arthritis: historical background and novel findings","volume":"63","author":"Sokolova","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025080602001242000_34.177.250046.29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001228"},{"key":"2025080602001242000_34.177.250046.30","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1007\/s10067-021-05808-2","article-title":"Serum anti-citrullinated protein antibodies and rheumatoid factor increase the risk of rheumatoid arthritis-related interstitial lung disease: a meta-analysis","volume":"40","author":"Xie","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025080602001242000_34.177.250046.31","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(22)00380-0"},{"key":"2025080602001242000_34.177.250046.32","doi-asserted-by":"crossref","first-page":"19253","DOI":"10.1038\/s41598-022-23180-2","article-title":"A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and interstitial lung disease in systemic sclerosis","volume":"12","author":"Ha","year":"2022","journal-title":"Sci Rep"},{"key":"2025080602001242000_34.177.250046.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.051391"},{"key":"2025080602001242000_34.177.250046.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00023-5"},{"key":"2025080602001242000_34.177.250046.35","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort","volume":"61","author":"Zanatta","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025080602001242000_34.177.250046.36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040465"},{"key":"2025080602001242000_34.177.250046.37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1513\/AnnalsATS.201808-565CME","article-title":"Interstitial pneumonia with autoimmune features","volume":"16","author":"Graney","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2025080602001242000_34.177.250046.38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41232-021-00167-6","article-title":"Updates on genetics in systemic sclerosis","volume":"41","author":"Ota","year":"2021","journal-title":"Inflamm Regen"},{"key":"2025080602001242000_34.177.250046.39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053736"},{"key":"2025080602001242000_34.177.250046.40","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-017-0623-9"},{"key":"2025080602001242000_34.177.250046.41","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00481-2020"},{"key":"2025080602001242000_34.177.250046.42","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00003214"},{"key":"2025080602001242000_34.177.250046.43","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/721608"},{"key":"2025080602001242000_34.177.250046.44","doi-asserted-by":"crossref","first-page":"L487","DOI":"10.1152\/ajplung.00301.2018","article-title":"Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A\/IL-17RA in human fibrotic interstitial lung disease","volume":"316","author":"Zhang","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2025080602001242000_34.177.250046.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0275-x"},{"key":"2025080602001242000_34.177.250046.46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032405"},{"key":"2025080602001242000_34.177.250046.47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.595811"},{"key":"2025080602001242000_34.177.250046.48","doi-asserted-by":"crossref","first-page":"e143626","DOI":"10.1172\/jci.insight.143626","article-title":"Molecular mapping of interstitial lung disease reveals a phenotypically distinct senescent basal epithelial cell population","volume":"6","author":"DePianto","year":"2021","journal-title":"JCI Insight"},{"key":"2025080602001242000_34.177.250046.49","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-021-00745-5"},{"key":"2025080602001242000_34.177.250046.50","doi-asserted-by":"crossref","first-page":"362","DOI":"10.21037\/jtd.2017.02.48","article-title":"Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease","volume":"9","author":"Yamakawa","year":"2017","journal-title":"J Thorac Dis"},{"key":"2025080602001242000_34.177.250046.51","doi-asserted-by":"crossref","first-page":"1098602","DOI":"10.3389\/fimmu.2023.1098602","article-title":"KL-6 levels in the connective tissue disease population: typical values and potential confounders \u2013 a retrospective, real-world study","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"2025080602001242000_34.177.250046.52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s42358-022-00269-w","article-title":"Serum MMP-9, SP-D, and VEGF levels reflect the severity of connective tissue disease-associated interstitial lung diseases","volume":"62","author":"Lv","year":"2022","journal-title":"Adv Rheumatol"},{"key":"2025080602001242000_34.177.250046.53","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202401-0238SO"},{"key":"2025080602001242000_34.177.250046.54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1504780112"},{"key":"2025080602001242000_34.177.250046.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.06.028"},{"key":"2025080602001242000_34.177.250046.56","doi-asserted-by":"crossref","first-page":"e86704","DOI":"10.1172\/jci.insight.86704","article-title":"Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis","volume":"1","author":"Naikawadi","year":"2016","journal-title":"JCI Insight"},{"key":"2025080602001242000_34.177.250046.57","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02314-2016"},{"key":"2025080602001242000_34.177.250046.58","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220022"},{"key":"2025080602001242000_34.177.250046.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07768-9"},{"key":"2025080602001242000_34.177.250046.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801562"},{"key":"2025080602001242000_34.177.250046.61","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002790"},{"key":"2025080602001242000_34.177.250046.62","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1093\/rheumatology\/keac152","article-title":"Associations of the MUC5B promoter variant with timing of interstitial lung disease and rheumatoid arthritis onset","volume":"61","author":"McDermott","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025080602001242000_34.177.250046.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.07.002"},{"key":"2025080602001242000_34.177.250046.64","doi-asserted-by":"crossref","first-page":"keae375","DOI":"10.1093\/rheumatology\/keae375","article-title":"Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis","volume":"22","author":"Velauthapillai","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025080602001242000_34.177.250046.65","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105767"},{"key":"2025080602001242000_34.177.250046.66","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001591"},{"key":"2025080602001242000_34.177.250046.67","first-page":"1604","article-title":"Hydroxychloroquine does not prevent the future development of rheumatoid arthritis in a population with baseline high levels of antibodies to citrullinated protein antigens and absence of inflammatory arthritis: interim analysis of the StopRA trial","volume":"74","author":"Deane","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025080602001242000_34.177.250046.68","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212763"},{"key":"2025080602001242000_34.177.250046.69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01193-X"},{"key":"2025080602001242000_34.177.250046.70","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02649-1"},{"key":"2025080602001242000_34.177.250046.71","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02650-8"},{"key":"2025080602001242000_34.177.250046.72","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200863"},{"key":"2025080602001242000_34.177.250046.73","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/acr.23837","article-title":"Impact and timing of smoking cessation on reducing risk of rheumatoid arthritis among women in the nurses\u2019 health studies","volume":"71","author":"Liu","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025080602001242000_34.177.250046.74","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.rmed.2016.05.030","article-title":"Nonspecific interstitial pneumonia preceding diagnosis of collagen vascular disease","volume":"117","author":"Kono","year":"2016","journal-title":"Respir Med"},{"key":"2025080602001242000_34.177.250046.75","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"2025080602001242000_34.177.250046.76","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.136929"},{"key":"2025080602001242000_34.177.250046.77","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00244-7"},{"key":"2025080602001242000_34.177.250046.78","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/rheumatology\/keae156","article-title":"Efficacy of methylprednisolone in very early systemic sclerosis: results of the \u201cHit Hard and Early'\u201d randomized controlled trial","volume":"64","author":"Kersten","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2025080602001242000_34.177.250046.79","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025080602001242000_34.177.250046.80","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2025080602001242000_34.177.250046.81","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028466"},{"key":"2025080602001242000_34.177.250046.82","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00337-2020"},{"key":"2025080602001242000_34.177.250046.83","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025080602001242000_34.177.250046.84","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3707-5"},{"key":"2025080602001242000_34.177.250046.85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30363-4"},{"key":"2025080602001242000_34.177.250046.86","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.reuma.2021.12.006","article-title":"Screening criteria for interstitial lung disease associated to rheumatoid arthritis: expert proposal based on Delphi methodology","volume":"19","author":"Narv\u00e1ez","year":"2023","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2025080602001242000_34.177.250046.87","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis","volume":"67","author":"Hoffmann-Vold","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025080602001242000_34.177.250046.88","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.2.9609016"},{"key":"2025080602001242000_34.177.250046.89","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.59"},{"key":"2025080602001242000_34.177.250046.90","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2019.19044"},{"key":"2025080602001242000_34.177.250046.91","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.42162","article-title":"A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease","volume":"74","author":"Juge","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025080602001242000_34.177.250046.92","doi-asserted-by":"crossref","first-page":"SI286","DOI":"10.1093\/rheumatology\/kead277","article-title":"Prevalence and mortality associations of interstitial lung abnormalities in rheumatoid arthritis within a multicentre prospective cohort of smokers","volume":"62","author":"McDermott","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025080602001242000_34.177.250046.93","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.04.061"},{"key":"2025080602001242000_34.177.250046.94","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","article-title":"Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society","volume":"8","author":"Hatabu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025080602001242000_34.177.250046.95","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00232-4"},{"key":"2025080602001242000_34.177.250046.96","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0"},{"key":"2025080602001242000_34.177.250046.97","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025080602001242000_34.177.250046.98","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202103-0714OC"},{"key":"2025080602001242000_34.177.250046.99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.933468"},{"key":"2025080602001242000_34.177.250046.100","doi-asserted-by":"crossref","first-page":"750753","DOI":"10.3389\/fimmu.2021.750753","article-title":"B cells in rheumatoid arthritis: pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"2025080602001242000_34.177.250046.101","doi-asserted-by":"crossref","first-page":"102453","DOI":"10.1016\/j.autrev.2019.102453","article-title":"Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: a systematic review","volume":"19","author":"Bellan","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025080602001242000_34.177.250046.102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725"},{"key":"2025080602001242000_34.177.250046.103","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7"},{"key":"2025080602001242000_34.177.250046.104","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01126-1"},{"key":"2025080602001242000_34.177.250046.105","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952"},{"key":"2025080602001242000_34.177.250046.106","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174"},{"key":"2025080602001242000_34.177.250046.107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"2025080602001242000_34.177.250046.108","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100643"},{"key":"2025080602001242000_34.177.250046.109","doi-asserted-by":"crossref","first-page":"152004","DOI":"10.1016\/j.semarthrit.2022.152004","article-title":"Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: clinical features, biomarkers, and treatment options","volume":"55","author":"Chen","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025080602001242000_34.177.250046.110","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2626"},{"key":"2025080602001242000_34.177.250046.111","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/1756-185X.14351","article-title":"Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: a single-center retrospective study from China","volume":"25","author":"Liu","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"2025080602001242000_34.177.250046.112","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025080602001242000_34.177.250046.113","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217455"},{"key":"2025080602001242000_34.177.250046.114","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004704"},{"key":"2025080602001242000_34.177.250046.115","unstructured":"Boehringer's nerandomilast meets primary endpoint in phase III study FIBRONEER\u2122-ILD, in progressive pulmonary fibrosis. 2025. www.boehringer-ingelheim.com\/human-health\/lung-diseases\/pulmonary-fibrosis\/nerandomilast-primary-endpoint-phase-3-fibroneer-ild-pulmonary-fibrosis Date last updated: 10 February 2025."},{"key":"2025080602001242000_34.177.250046.116","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202401-0048PP"},{"key":"2025080602001242000_34.177.250046.117","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220541"},{"key":"2025080602001242000_34.177.250046.118","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1113ST"},{"key":"2025080602001242000_34.177.250046.119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2025080602001242000_34.177.250046.120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2025080602001242000_34.177.250046.121","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30554-3"},{"key":"2025080602001242000_34.177.250046.122","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"2025080602001242000_34.177.250046.123","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1513\/AnnalsATS.202301-054OC","article-title":"Mycophenolate in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"21","author":"Herman","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2025080602001242000_34.177.250046.124","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202108-980OC"},{"key":"2025080602001242000_34.177.250046.125","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1513\/AnnalsATS.202301-053OC","article-title":"Cyclophosphamide in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"21","author":"Barnes","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2025080602001242000_34.177.250046.126","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1513\/AnnalsATS.202301-055OC","article-title":"Rituximab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"21","author":"Macrea","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2025080602001242000_34.177.250046.127","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/ph7050530","article-title":"Barriers to the access and use of rituximab in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia: a physician survey","volume":"7","author":"Baer Ii","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025080602001242000_34.177.250046.128","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00359-9"},{"key":"2025080602001242000_34.177.250046.129","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204"},{"key":"2025080602001242000_34.177.250046.130","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"2025080602001242000_34.177.250046.131","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0108"},{"key":"2025080602001242000_34.177.250046.132","doi-asserted-by":"publisher","DOI":"10.1002\/art.22580"},{"key":"2025080602001242000_34.177.250046.133","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213708"},{"key":"2025080602001242000_34.177.250046.134","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201802-079OC"},{"key":"2025080602001242000_34.177.250046.135","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.11.052"},{"key":"2025080602001242000_34.177.250046.136","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key213"},{"key":"2025080602001242000_34.177.250046.137","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00107-7"},{"key":"2025080602001242000_34.177.250046.138","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02071-2022"},{"key":"2025080602001242000_34.177.250046.139","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151322"},{"key":"2025080602001242000_34.177.250046.140","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30036-9"},{"key":"2025080602001242000_34.177.250046.141","first-page":"0520","article-title":"Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the Scleroderma Lung Study III","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025080602001242000_34.177.250046.142","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1513\/AnnalsATS.202301-081OC","article-title":"Nintedanib therapy alone and combined with mycophenolate in patients with systemic sclerosis-associated interstitial lung disease: systematic reviews and meta-analysis","volume":"21","author":"Herman","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2025080602001242000_34.177.250046.143","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease \u2013 a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"key":"2025080602001242000_34.177.250046.144","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000502551","article-title":"Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality","volume":"98","author":"Hyldgaard","year":"2019","journal-title":"Respiration"},{"key":"2025080602001242000_34.177.250046.145","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/jcm10040874","article-title":"Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospective cohort study","volume":"10","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"J Clin Med"},{"key":"2025080602001242000_34.177.250046.146","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00357-2015"},{"key":"2025080602001242000_34.177.250046.147","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.03.027"},{"key":"2025080602001242000_34.177.250046.148","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.21037\/jtd-22-1820","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease in a multi-center registry cohort","volume":"15","author":"Marcoux","year":"2023","journal-title":"J Thorac Dis"},{"key":"2025080602001242000_34.177.250046.149","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113354"},{"key":"2025080602001242000_34.177.250046.150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2213-2600(21)00354-4","article-title":"Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"10","author":"Naccache","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025080602001242000_34.177.250046.151","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/resp.14609","article-title":"Serum C-reactive protein is associated with earlier mortality across different interstitial lung diseases","volume":"29","author":"Stock","year":"2024","journal-title":"Respirology"},{"key":"2025080602001242000_34.177.250046.152","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06623-7"},{"key":"2025080602001242000_34.177.250046.153","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00260-0"},{"key":"2025080602001242000_34.177.250046.154","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121043"},{"key":"2025080602001242000_34.177.250046.155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir Med"},{"key":"2025080602001242000_34.177.250046.156","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"key":"2025080602001242000_34.177.250046.157","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4382-x"},{"key":"2025080602001242000_34.177.250046.158","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","article-title":"Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025080602001242000_34.177.250046.159","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025080602001242000_34.177.250046.160","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05854-w"},{"key":"2025080602001242000_34.177.250046.161","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102830"},{"key":"2025080602001242000_34.177.250046.162","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"key":"2025080602001242000_34.177.250046.163","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/jcm12030957","article-title":"Evolution of rheumatoid-arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a retrospective exploratory study","volume":"12","author":"Venerito","year":"2023","journal-title":"J Clin Med"},{"key":"2025080602001242000_34.177.250046.164","doi-asserted-by":"crossref","first-page":"151959","DOI":"10.1016\/j.semarthrit.2022.151959","article-title":"Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review","volume":"53","author":"McPherson","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025080602001242000_34.177.250046.165","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002795"},{"key":"2025080602001242000_34.177.250046.166","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key188"},{"key":"2025080602001242000_34.177.250046.167","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00441-2023"},{"key":"2025080602001242000_34.177.250046.168","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.03.023"},{"key":"2025080602001242000_34.177.250046.169","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1513\/AnnalsATS.202102-123ED","article-title":"Broad adoption of antifibrotics in idiopathic pulmonary fibrosis: still a long way to go","volume":"18","author":"Assayag","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2025080602001242000_34.177.250046.170","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/ijerph21050647","article-title":"Improving accessibility to patients with interstitial lung disease (ILD): barriers to early diagnosis and timely treatment in Latin America","volume":"21","author":"Figueiredo","year":"2024","journal-title":"Int J Environ Res Public Health"},{"key":"2025080602001242000_34.177.250046.171","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.04.021"},{"key":"2025080602001242000_34.177.250046.172","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01519-2020"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0046-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T09:00:42Z","timestamp":1754470842000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0046-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":172,"journal-issue":{"issue":"177","published-online":{"date-parts":[[2025,7,23]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1183\/16000617.0046-2025"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0046-2025","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}